Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.780 -0.110 (-2.25%)
Streaming Delayed Price Updated: 2:54 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 218,890
Open 4.920
Bid (Size) 4.750 (5)
Ask (Size) 4.950 (5)
Prev. Close 4.890
Today's Range 4.670 - 4.970
52wk Range 3.560 - 28.60
Shares Outstanding 9,600,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top stock movements in today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
BlueBird Shares Are Up Today: What's Going On?
Bluebird Bio Inc. (NASDAQ: BLUE) shares are trading higher Monday after the company received an unsolicited takeover offer from Ayrmid Ltd. 
Via Benzinga

Performance

YTD
-45.0%
-45.0%
1 Month
+16.3%
+16.3%
3 Month
-51.8%
-51.8%
6 Month
-54.1%
-54.1%
1 Year
-80.6%
-80.6%

More News

Read More
Monday's session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
From bluebird bio, Inc.
Via Business Wire
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
From Kahn Swick & Foti, LLC
Via Business Wire
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Via Benzinga
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
From Kahn Swick & Foti, LLC
Via Business Wire
Top movers analysis one hour before the close of the markets on 2025-02-21: top gainers and losers in today's session.
Via Chartmill
Dow Tumbles Over 700 Points; US Services PMI Falls In February
Via Benzinga
Topics Stocks
Exposures US Equities
Top movers in Friday's session
Via Chartmill
Stocks Firmly Lower As Consumer Sentiment Weakens
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Gapping stocks in Friday's session
Via Chartmill
These stocks are moving in today's pre-market session
Via Chartmill
Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public Shareholders
From Ademi LLP
Via Business Wire
What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
Via Benzinga
BLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
From bluebird bio, Inc.
Via Business Wire
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc.
Via Business Wire
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Via Benzinga
bluebird bio Announces 1-for-20 Reverse Stock Split
From bluebird bio, Inc.
Via Business Wire

Frequently Asked Questions

Is bluebird bio, Inc. - Common Stock publicly traded?
Yes, bluebird bio, Inc. - Common Stock is publicly traded.
What exchange does bluebird bio, Inc. - Common Stock trade on?
bluebird bio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for bluebird bio, Inc. - Common Stock?
The ticker symbol for bluebird bio, Inc. - Common Stock is BLUE on the Nasdaq Stock Market
What is the current price of bluebird bio, Inc. - Common Stock?
The current price of bluebird bio, Inc. - Common Stock is 4.780
When was bluebird bio, Inc. - Common Stock last traded?
The last trade of bluebird bio, Inc. - Common Stock was at 04/04/25 02:54 PM ET
What is the market capitalization of bluebird bio, Inc. - Common Stock?
The market capitalization of bluebird bio, Inc. - Common Stock is 45.89M
How many shares of bluebird bio, Inc. - Common Stock are outstanding?
bluebird bio, Inc. - Common Stock has 46M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.